doi: 10.1161/hy1201.100589
(Hypertension. 2001;38:1382.)
© 2001 American Heart Association, Inc.
Fourth International Seminar on Cardiovascular Biology and Medicine: Part II |
Role of the Renin-Angiotensin System in Vascular Diseases
Expanding the Field
From the Laboratory of Vascular and Renal Pathology, Fundación Jiménez Díaz, Universidad Autónoma Madrid, (M.R.-O., O.L., M.R., V.E., Y.S., J.E.), Madrid, Spain; and Universidad Austral (S.M.), Valdivia, Chile.
Correspondence to M. Ruiz-Ortega, Renal and Vascular Research Laboratory, Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040 Madrid, Spain. E-mail: mruizo{at}fjd.es
Abstract
The renin-angiotensin system (RAS) has emerged as one of the essential links in the pathophysiology of vascular disease. Angiotensin (Ang) II, the main peptide of the RAS, was considered as a vasoactive hormone, but in the past years, this view has been modified to a growth factor that regulates cell proliferation/apoptosis and fibrosis. Recently, this view has been enlarged with a novel concept: Ang II participates in the inflammatory response, acting as a proinflammatory mediator. In resident vascular cells, Ang II produces chemokines, cytokines, and adhesion molecules, which contribute to the migration of inflammatory cells into the tissue injury. Ang II is also a chemotactic and mitogenic factor for mononuclear cells. The molecular mechanisms of Ang II–induced vascular damage are mediated by the activation of transcription factors, redox signaling systems, and production of endogenous growth factors. In addition, other components of the RAS could also be involved in the pathogenesis of cardiovascular diseases. The Ang II degradation product Ang III shares some of its properties with Ang II, including chemotaxis and production of growth factors and chemokines. All these data clearly demonstrate that Ang II is a true cytokine, show the complexity of the RAS in pathological processes, and provide some mechanistic responses of the beneficial effects of the treatment with RAS blockers in cardiovascular diseases.
Key Words: angiotensin II • inflammation • fibrosis • vascular damage • renal damage
This article has been cited by other articles:
 |
|
 |
|
  R. N Easter, Qilin Chan, B. Lai, E. L Ritman, J. A Caruso, and Zhenyu Qin Vascular metallomics: Copper in the vasculature Vascular Medicine, February 1, 2010; 15(1): 61 - 69. [Abstract] [PDF]
|
|
|
|
 |
|
 A. GLUBA, M. BANACH, D. P. MIKHAILIDIS, and J. RYSZ Genetic Determinants of Cardiovascular Disease: The Renin-Angiotensin-Aldosterone System, Paraoxonases, Endothelin-1, Nitric Oxide Synthase and Adrenergic Receptors In Vivo, September 1, 2009; 23(5): 797 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Khakoo, R. L. Sidman, R. Pasqualini, and W. Arap Does the Renin-Angiotensin System Participate in Regulation of Human Vasculogenesis and Angiogenesis? Cancer Res., November 15, 2008; 68(22): 9112 - 9115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vaajanen, H. Vapaatalo, H. Kautiainen, and O. Oksala Angiotensin (1-7) Reduces Intraocular Pressure in the Normotensive Rabbit Eye Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2557 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Machado, E. P. B. Poppi, C. Fanelli, D. M. A. C. Malheiros, R. Zatz, and C. K. Fujihara AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1345 - F1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sriramula, M. Haque, D. S.A. Majid, and J. Francis Involvement of Tumor Necrosis Factor-{alpha} in Angiotensin II-Mediated Effects on Salt Appetite, Hypertension, and Cardiac Hypertrophy Hypertension, May 1, 2008; 51(5): 1345 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vinh, R. E. Widdop, G. R. Drummond, and T. A. Gaspari Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice Cardiovasc Res, January 1, 2008; 77(1): 178 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-X. Zhang, X.-M. Lu, S. Kimura, and A. Nishiyama Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation Cardiovasc Res, November 1, 2007; 76(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gavazzi, C. Deffert, C. Trocme, M. Schappi, F. R. Herrmann, and K.-H. Krause NOX1 Deficiency Protects From Aortic Dissection in Response to Angiotensin II Hypertension, July 1, 2007; 50(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Parmentier, C. Zhang, A. Estes, S. Schaefer, and K. U. Malik Essential role of PKC-{zeta} in normal and angiotensin II-accelerated neointimal growth after vascular injury Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1602 - H1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Arenas, S. J. Armstrong, Y. Xu, and S. T. Davidge Tumor Necrosis Factor-{alpha} and Vascular Angiotensin II in Estrogen-Deficient Rats Hypertension, September 1, 2006; 48(3): 497 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Hunton, W. G. Barnes, J. Kim, X.-R. Ren, J. D. Violin, E. Reiter, G. Milligan, D. D. Patel, and R. J. Lefkowitz {beta}-Arrestin 2-Dependent Angiotensin II Type 1A Receptor-Mediated Pathway of Chemotaxis Mol. Pharmacol., April 1, 2005; 67(4): 1229 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Watanabe, T. A. Barker, and B. C. Berk Angiotensin II and the Endothelium: Diverse Signals and Effects Hypertension, February 1, 2005; 45(2): 163 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lundequist, E. Tchougounova, M. Abrink, and G. Pejler Cooperation between Mast Cell Carboxypeptidase A and the Chymase Mouse Mast Cell Protease 4 in the Formation and Degradation of Angiotensin II J. Biol. Chem., July 30, 2004; 279(31): 32339 - 32344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Sokol, E. L. Portnay, J. P. Curtis, M. A. Nelson, P. R. Hebert, J. F. Setaro, and J. M. Foody Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke Neurology, July 27, 2004; 63(2): 208 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Steinman Immune Therapy for Autoimmune Diseases Science, July 9, 2004; 305(5681): 212 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yousufuddin, D. J. Cook, R. C. Starling, A. Abdo, P. Paul, E. M. Tuzcu, N. B. Ratliff, P. M. McCarthy, J. B. Young, and M. H. Yamani Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1565 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Guo, E. Mascareno, and M. A. Q. Siddiqui Distinct Components of Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway Mediate the Regulation of Systemic and Tissue Localized Renin-Angiotensin System Mol. Endocrinol., April 1, 2004; 18(4): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Arenas, Y. Xu, P. Lopez-Jaramillo, and S. T. Davidge Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-{alpha} Am J Physiol Cell Physiol, April 1, 2004; 286(4): C779 - C784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yousufuddin, S. Haji, R. C. Starling, E. M. Tuzcu, N. B. Ratliff, D. J. Cook, A. Abdo, Y. Saad, S. S. Karnik, D. Wang, et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation Eur. Heart J., March 1, 2004; 25(5): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Farjah, T. L. Washington, B. P. Roxas, D. L. Geenen, and R. S. Danziger Dietary NaCl Regulates Renal Aminopeptidase N: Relevance to Hypertension in the Dahl Rat Hypertension, February 1, 2004; 43(2): 282 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Widlansky, N. Gokce, J. F. Keaney Jr, and J. A. Vita The clinical implications of endothelial dysfunction J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1149 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Gates, C. L. Gentile, D. R. Seals, and D. D. Christou Adiposity Contributes to Differences in Left Ventricular Structure and Diastolic Function with Age in Healthy Men J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4884 - 4890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bataller, E. Gabele, R. Schoonhoven, T. Morris, M. Lehnert, L. Yang, D. A. Brenner, and R. A. Rippe Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver Am J Physiol Gastrointest Liver Physiol, August 8, 2003; 285(3): G642 - G651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Taubman Angiotensin II: A Vasoactive Hormone With Ever-Increasing Biological Roles Circ. Res., January 10, 2003; 92(1): 9 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Muller, E. Shagdarsuren, J.-K. Park, R. Dechend, E. Mervaala, F. Hampich, A. Fiebeler, X. Ju, P. Finckenberg, J. Theuer, et al. Immunosuppressive Treatment Protects Against Angiotensin II-Induced Renal Damage Am. J. Pathol., November 1, 2002; 161(5): 1679 - 1693. [Abstract] [Full Text] [PDF]
|
|